



Geriatrics • Educational evidence summary

Anticholinergic burden and vision-related symptoms

This geriatric evidence summary examines anticholinergic burden and vision-related symptoms.

UnifiedACB • Published October 3, 2026 • Updated October 4, 2026

[Read the current article](#)

<https://unifiedacb.com/articles/026-anticholinergic-burden-and-vision-related-symptoms/>

Why start with the symptom instead of the score?

“Vision problems” can describe blur, difficulty focusing, discomfort or other changes. The timing, severity and accompanying features matter. A medication classification does not identify which of those problems is present or distinguish a medication effect from another eye condition.

The purpose of an anticholinergic review is to identify a plausible exposure question. It should complement, rather than replace, an appropriate eye or medical assessment.

Can anticholinergic medicines cause blurred vision?

Some product labels explicitly include blurred vision among relevant adverse effects. The [oxybutynin extended-release prescribing information](#) is one example. That statement is product-specific evidence; it is more precise than inferring the same likelihood from every nonzero ordinal category.

A listed adverse effect does not prove that the medicine caused a person’s current symptom. Actual exposure, timing and alternative explanations still need assessment. The source category alone cannot establish severity or duration.

Does a high score mean the person has glaucoma?

No. A source-scale category is not an eye examination or a glaucoma diagnosis. It does not measure intraocular pressure or identify the anatomy relevant to a particular glaucoma concern. Treating the category as a diagnostic result would give it a role it was not designed to perform.

The [named oxybutynin label](#) specifies uncontrolled narrow-angle glaucoma in its contraindications. The subtype and qualification matter. It would be inaccurate to replace that wording with a blanket statement about every person who has any form of glaucoma.

Does an eye-drop route make all other evidence irrelevant?



No route should be handled by an automatic assumption. A source may explicitly address or exclude a particular route, while another source may provide only an ingredient-level entry. The evidence must be read at the level of detail actually available.

UnifiedACB retains source labels and route/formulation notes in the [public record](#). A finding about oral use should not silently become a statement about an ophthalmic preparation, and a route exclusion from one criterion should not become a general assurance of safety. If the route is unknown and materially changes the answer, it should be clarified.

What details are useful for a medication review?

Record the exact product, route, schedule and recent changes. Describe when the visual symptom occurs relative to use, while avoiding the assumption that temporal association proves causation. Include nonprescription products and medicines used only occasionally.

The actual functional effect also matters: difficulty reading labels, navigating a familiar space or performing usual tasks gives the clinician a concrete concern to assess. A numerical burden total does not capture those outcomes.

Can a low or missing category rule out a medication contribution?

No. A source-specific zero is limited to the method that published it, and an absent entry is not a zero at all. A medicine may also affect vision through mechanisms outside the particular anticholinergic scale. The full product information and clinical assessment may therefore be relevant even when the table appears reassuring.

Conversely, a high category does not establish that every visual symptom should be attributed to the medicine. Keeping both boundaries visible prevents the score from prematurely narrowing the assessment.

If a care partner reports the change, record what was actually observed—for example, a new difficulty reading a familiar label—rather than assigning an eye diagnosis from the behavior. The observation can support assessment while the cause remains uncertain. It should remain separate from the medication classification in the review note.

Should the person wait for the medication comparison before seeking care?

New or concerning visual symptoms deserve clinical assessment on their own merits. The directory cannot rule out an eye condition or determine urgency from a medication list. A product-specific warning can help explain why review is warranted, but it cannot replace an examination.

The practical next step in an evidence discussion is a precise question: which product warning applies, does the route match, and what symptom needs assessment? That is more useful than treating “anticholinergic” as a complete explanation for every eye complaint.



References

1. American Geriatrics Society 2023 Updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. *J Am Geriatr Soc.* 2023;71:2052-2081. [Source](#)
2. Vennard O, Stewart C, Tolia M, Soiza RL, Myint PK. Anticholinergic Medication Burden Scales: A Systematic Review. *J Am Geriatr Soc.* 2026;74(6):1771-1784. [Source](#)
3. American Geriatrics Society Beers Criteria Alternatives Panel. Alternative Treatments to Selected Medications in the 2023 AGS Beers Criteria. *J Am Geriatr Soc.* 2025;73:2657-2677. [Source](#)
4. Fox C, et al. Effect of medications with anti-cholinergic properties on cognitive function, delirium, physical function and mortality: a systematic review. *Age Ageing.* 2014;43:604-615. [Source](#)
5. Ruxton K, Woodman RJ, Mangoni AA. Drugs with anticholinergic effects and cognitive impairment, falls and all-cause mortality in older adults: a systematic review and meta-analysis. *Br J Clin Pharmacol.* 2015;80(2):209-220. doi:10.1111/bcp.12617. [Source](#)
6. Egberts A, et al. Anticholinergic Drug Burden and Delirium: A Systematic Review. *J Am Med Dir Assoc.* 2021;22:65-73.e4. [Source](#)
7. DailyMed. Oxybutynin chloride extended-release tablets. Official prescribing information; set ID 7d2332b4-9e48-4bb2-a2c3-75e16e1d455b. [Source](#)
8. UnifiedACB. Preserved public source-observation dataset, v3.0 RC12 final; inspected for this editorial revision. [Source](#)

Explore the evidence

[Ask UnifiedACB](#) about a medication or source, browse the [Medication Library](#), or read the [methodology](#).

Disclosure

Funding: None. Conflict of interest: None declared for the UnifiedACB educational project.

Educational evidence summary. This content does not provide patient-specific medical advice and does not replace clinical judgment, medication reconciliation, or prescribing guidance.